Analyst Research Summary: Bristol-Myers Squibb Company (NYSE:BMY)

Posted February 18, 2017

The 5 year historical dividend growth of Bristol-Myers Squibb Company (BMY) is at the rate of 2.78% while the R-Squared dividend growth is 0.95.

Other hedge funds and other institutional investors have also made changes to their positions in the company. During the same quarter in the previous year, the company posted $0.38 EPS. ROIC is a metric that can be used to gauge the efficiency of a certain company at allocating controlled capital into investments that are profitable. Penserra Capital Management LLC raised its position in shares of Bristol-Myers Squibb Company by 95.3% in the third quarter.

When we look at the recommendation trends, the stock presently has an average brokerage recommendation of 4.6. The stock now has a Market Cap of $91.72B. Cutler Investment Counsel LLC now owns 123,509 shares of the biopharmaceutical company's stock worth $6,660,000 after buying an additional 1,139 shares during the period. Mcmillion Capital Management Inc. increased its stake in Bristol-Myers Squibb Company by 1.8% in the third quarter.

The Average Volume of the company is 11.85 Million, while the Relative Volume of the company is 1. The new indicated annual dividend based on announced dividend per share is $1.56. Robert Novy-Marx has provided investors with insights on finding high-quality value stocks.

Bristol-Myers Squibb Company (NYSE:BMY) opened at 54.28 on Friday. The median one-year price target of 21 analysts covering the company is $55.00, which suggests the stock could still rise over 1 percent. According to these analysts, the Low Revenue Estimate for Bristol-Myers Squibb Company is 4.55 Billion and the High Revenue Estimate is 4.92 Billion. The stock's current distance from 20-Day Simple Moving Average (SMA20) is 8.34% where SMA50 and SMA200 are 0.14% and -9.09% respectively.

Bristol-Myers Squibb Company (BMY) failed to surprise the stock market in its last reported earnings when it earned $0.63 a piece versus the consensus-estimated $0.67. According to Thomson Reuters, analysts are projecting a consensus target price of $55.18 on company shares. The stock has 52-week high of $39.78 and 52-Week low of $20. The firm has Profit Margin of positive 22.90%.

The firm also recently declared a quarterly dividend, which was paid on Wednesday, February 1st. Stockholders of record on Friday, January 6th were issued a $0.39 dividend. This represents a $1.56 dividend on an annualized basis and a yield of 2.87%. The company has volume of 11.49 Million shares. The ex-dividend date of this dividend was Wednesday, January 4th. This ranking was created by James O'Shaughnessy using six different valuation ratios including price to book value, price to sales, EBITDA to EV, price to cash flow, price to earnings, and shareholder yield.

This piece of content was reported by Community Financial News and is the property of of Community Financial News.

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products.

A number of research firms have recently commented on BMY. Zacks Investment Research lowered shares of Bristol-Myers Squibb Company from a "hold" rating to a "sell" rating in a research note on Thursday, October 20th.

Bristol-Myers Squibb Company closed its last trading session at $53.71 with the gain of 2.46%. Finally, Vetr downgraded shares of Bristol-Myers Squibb Company from a "strong-buy" rating to a "buy" rating and set a $58.77 price objective for the a report on Monday, November 7th. Exelon Corporation has 6 buy ratings, 7 holds and 0 sells even after the stock tumbled -3.89% from its high of $37.7 to a $32.36 billion market value through 2/15/2017.